Amneal’s Biosimilar Candidate Positive Topline Results
Amneal Pharmaceuticals announced positive topline results from a Phase 3 trial of ADL-018, a biosimilar to XOLAIR® (omalizumab), developed...
Assembly Biosciences Reports Positive Topline Results From Phase 1b Trial of Next-Gen Capsid Assembly Modulator ABI-4334
Assembly Biosciences announced positive topline results from a Phase 1b study of ABI-4334, a next-generation capsid assembly modulator (CAM),...
Soquelitinib IND Approved for Atopic Dermatitis Trial in China
Corvus Pharmaceuticals‘ partner in China, Angel Pharma, has received approval from the China National Medical Products Administration (NMPA) to...
Positive Top-Line Results for Xolair® Biosimilar Efficacy Study
Alvotech, Kashiv Biosciences, and Advanz Pharma announced positive topline results from a phase 3 study of AVT23 (ADL-018), a...
Exact Therapeutics Doses First Patient in Phase 2 Pancreatic Cancer Trial
EXACT Therapeutics has initiated its Phase 2 ENACT trial, evaluating Acoustic Cluster Therapy (ACT) combined with standard chemotherapy in...
Tern-601 GLP-1R Agonist Shows Promise for Obesity Treatment
Terns Pharmaceuticals announced data from a completed Phase 1 study and full enrollment of its Phase 2 FALCON trial...
IMDX Reports Strong Kidney Transplant Rejection Test Data
iMDx (Nasdaq: IMDX) announced positive results from a head-to-head study comparing its flagship digital PCR-based dd-cfDNA test kit, GraftAssureIQ,...
Sana Biotechnology: Positive Results in Type 1 Diabetes Islet Cell Transplant Study
Sana Biotechnology announced six-month follow-up results from a first-in-human study transplanting HIP-modified (hypoimmune) allogeneic islet cells (UP421) into a...
Revolutionary Daraxonrasib Wins FDA Breakthrough Therapy for Pancreatic Cancer
Revolution Medicines received Breakthrough Therapy Designation from the FDA for daraxonrasib, its RAS(ON) inhibitor, targeting previously treated metastatic pancreatic...
CUE Biopharma to Advance IND for CUE-401 in Autoimmune Disease
Cue Biopharma received positive Pre-Investigational New Drug (Pre-IND) feedback from the FDA for CUE-401, a first-in-class bispecific molecule designed...